单采血小板输注患者血小板聚集的风险因子探讨

doi:10.3760/cma.j.cn441417-20241211-16019

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (16): 2734-2738.DOI: 10.3760/cma.j.cn441417-20241211-16019

单采血小板输注患者血小板聚集的风险因子探讨

唐琳¹ 陈玉平² 巨小英³

¹宝鸡市人民医院输血科，宝鸡 721000；²江苏力博医药生物技术股份有限公司，无锡 214400；³宝鸡第三医院输血科，宝鸡 721000

收稿日期:2024-12-11 出版日期:2025-08-15 发布日期:2025-08-28
通讯作者: 巨小英，Email：juxiaoying040506@163.com
基金资助:
江苏省科技成果转化专项资金项目（BA2017047）

Risk factors of platelet aggregation in patients undergoing apheresis platelet transfusion

Tang Lin¹, Chen Yuping², Ju Xiaoying³

¹Department of Blood Transfusion, Baoji People's Hospital, Baoji 721000, China; ²Jiangsu Libo Pharmaceutical Biotechnology Co., Ltd., Wuxi 214400, China; ³Department of Blood Transfusion, Baoji Third Hospital, Baoji 721000, China

Received:2024-12-11 Online:2025-08-15 Published:2025-08-28
Contact: Ju Xiaoying, Email: juxiaoying040506@163.com
Supported by:
Project Funded by Scientific and Technological Achievement Transformation Program in Jiangsu (BA2017047)

摘要/Abstract

摘要：

目的　基于反应范围模型分析单采血小板（platelet，PLT）输注患者PLT聚集的风险因子。方法　回顾性分析2021年5月至2024年7月于宝鸡市人民医院行单采PLT输注的341例患者的临床资料，其中男180例，女161例，年龄51（39，65）岁。依据有无发生PLT聚集将患者分为发生组和未发生组。基于患者临床特征以及专家共识、指南在专家指导下设计反应范围模型，对单采PLT输注患者PLT聚集的风险因子进行研究假设。比较发生组和未发生组临床资料。采用logistic回归模型分析单采PLT输注患者PLT聚集的影响因素。采用t检验、Mann-Whitney U检验、χ²检验进行统计分析。结果　341例单采PLT输注患者PLT聚集发生率为11.14%（38/341）。发生组年龄、单采PLT库存时间>3 d占比、PLT输注次数高于未发生组［58.0（40.5，72.0）岁比48.0（38.0，60.0）岁、36.84%（14/38）比20.13%（61/303）、（7.03±1.55）次比（5.10±1.09）次］，输注前PLT计数低于未发生组［10.5（7.0，13.0）×10⁹/L比16.0（11.0，20.0）×10⁹/L］，差异均有统计学意义（均P<0.05）。logistic回归模型分析结果示，年龄大［比值比（OR）=1.183，95%置信区间（CI）1.019～1.373］、输注前PLT计数低（OR=0.793，95%CI 0.673～0.935）、单采PLT库存时间>3 d（OR=2.793，95%CI 1.079～7.225）、PLT输注次数多（OR=1.511，95%CI 1.174～1.946）均是单采PLT输注患者PLT聚集的风险因素（均P<0.05）。结论　年龄大、输注前PLT计数低、单采PLT库存时间>3 d、PLT输注次数多均是单采PLT输注患者PLT聚集的风险因子。

关键词:

血小板输注, 单采血小板, 血小板聚集, 风险因子, 反应范围模型

Abstract:

Objective　To analyze the risk factors of platelet aggregation in patients undergoing apheresis platelet (PLT) transfusion based on the reactive scope model. Methods　A retrospective analysis was conducted on the clinical data of 341 patients who underwent apheresis PLT transfusion in Baoji People's Hospital from May 2021 to July 2024, including 180 males and 161 females who were 51 (39, 65) years old. The patients were divided into an occurrence group and a non-occurrence group based on the presence or absence of PLT aggregation. Based on the patients' clinical characteristics, expert consensus, and guidelines, a reactive scope model was designed under expert guidance to study the risk factors of PLT aggregation in the patients. The clinical data of the occurrence group and the non-occurrence group were compared. The influencing factors of PLT aggregation in the patients were analyzed by the logistic regression model. t test, Mann-Whitney U test, and χ² test were used for the statistical analysis. Results　The incidence of PLT aggregation in the 341 patients was 11.14% (38/341). The age, the proportion of single dose PLT inventory time > 3 d, the number of PLT transfusion of the occurrence group were higher than those of the non-occurrence group [58 (40.5, 72.0) years vs. 48.0 (38.0, 60.0) years, 36.84% (14/38) vs. 20.13% (61/303), and (7.03±1.55) times vs. (5.10±1.09) times], and the PLT count before transfusion was lower [10.5 (7.0, 13.0) ×10⁹/L vs. [16.0 (11.0, 20.0) ×10⁹/L], with statistical differences (all P<0.05). The results of logistic regression model analysis showed that older age [odds ratio (OR)=1.183, 95% confidence interval (CI) 1.019-1.373], lower PLT count before transfusion (OR=0.793, 95%CI 0.673-0.935), single dose PLT inventory time > 3 d (OR=2.793, 95%CI 1.079-7.225), and multiple PLT infusions (OR=1.511, 95%CI 1.174-1.946) were all risk factors of PLT aggregation in the patients (all P<0.05). Conclusion　Older age, lower PLT count before transfusion, single dose PLT inventory time > 3 d, and multiple PLT infusions are all risk factors of PLT aggregation in patients undergoing apheresis PLT transfusion.

Key words:

Platelet transfusion, Apheresis platelet, Platelet aggregation, Risk factors, Reactive scope model

唐琳陈玉平巨小英.

单采血小板输注患者血小板聚集的风险因子探讨 [J]. 国际医药卫生导报, 2025, 31(16): 2734-2738.

Tang Lin, Chen Yuping, Ju Xiaoying.

Risk factors of platelet aggregation in patients undergoing apheresis platelet transfusion [J]. International Medicine and Health Guidance News, 2025, 31(16): 2734-2738.

参考文献

[1] Karlström C, Gryfelt G, Schmied L, et al. Platelet transfusion improves clot formation and platelet function in severely thrombocytopenic haematology patients[J]. Br J Haematol, 2022, 196(1): 224-233. DOI: 10.1111/bjh.17820.
[2] Skipper MT, Rubak P, Stentoft J, et al. Evaluation of platelet function in thrombocytopenia[J]. Platelets, 2018, 29(3):270-276. DOI:10.1080/09537104.2017.1296566.
[3] Tohidi-Esfahani I, Tan S, Tan CW, et al. Platelet procoagulant potential is reduced in platelet concentrates ex vivo but appears restored following transfusion[J]. Transfusion, 2021, 61(12):3420-3431. DOI:10.1111/trf.16695.
[4] Llobet D, Vallvé C, Tirado I, et al. Platelet hyperaggregability and venous thrombosis risk: results from the RETROVE project[J]. Blood Coagul Fibrinolysis, 2021, 32(2):122-131. DOI: 10.1097/MBC.0000000000001006.
[5] 程文晋,汤辉伟,纪淑华,等. 单采血小板聚集的影响因素分析[J]. 基层医学论坛, 2021, 25(22):3213-3215. DOI: 10.19435/j.1672-1721.2021.22.051.
[6] 刘宇健,李晓帆,林绮文,等. 献血者凝血状态对其捐献的单采血小板体外聚集现象的影响[J]. 中国输血杂志, 2023, 36(8):728-731. DOI:10.13303/j.cjbt.issn.1004-549x.2023.08.018.
[7] Hadley JB, Kelher MR, Coleman JR, et al. Hormones, age, and sex affect platelet responsiveness in vitro[J]. Transfusion, 2022, 62(9):1882-1893. DOI:10.1111/trf.17054.
[8] Romero LM, Dickens MJ, Cyr NE. The Reactive Scope Model - a new model integrating homeostasis, allostasis, and stress[J]. Horm Behav, 2009, 55(3):375-389. DOI:10.1016/j.yhbeh.2008.12.009.
[9] 中国输血协会临床输血学专业委员会«血液成分输注临床路径»制订协作组. 血液成分输注临床路径专家共识(2018年)[J]. 临床血液学杂志,2018,31(2):81-84. DOI:10.13201/j.issn.1004-2806-b.2018.02.001.
[10] 常颖. 血小板输注过程发生血小板聚集的预防性护理[J]. 血栓与止血学,2017,23(6):1060-1061. DOI:10.3969/j.issn.1009-6213.2017.06.059.
[11] Poscablo DM, Worthington AK, Smith-Berdan S, et al. An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis[J]. Cell, 2024, 187(12):3090-3107.e21. DOI: 10.1016/j.cell.2024.04.018.
[12] Tian J, Cheng LH, Cui X, et al. Investigating the effect of age on platelet ultrastructure using transmission electron microscopy[J]. Int Wound J, 2019, 16(6): 1457-1463. DOI:10.1111/iwj.13214.
[13] 盛建龙,何非,程诚,等. 年龄对经皮冠脉介入治疗术后血小板聚集率的影响[J]. 实用医学杂志, 2019, 35(19): 3022-3026. DOI:10.3969/j.issn.1006-5725.2019.19.010.
[14] Schultz-Lebahn A, Skipper MT, Hvas AM, et al. Optimized tool for evaluation of platelet function measured by impedance aggregometry[J]. Platelets, 2021, 32(6):842-845. DOI:10.1080/09537104.2020.1809644.
[15] Zarama V, Revelo-Noguera J, Quintero JA, et al. Prophylactic platelet transfusion and risk of bleeding associated with ultrasound-guided central venous access in patients with severe thrombocytopenia[J]. Acad Emerg Med, 2023, 30(6):644-652. DOI:10.1111/acem.14651[J].
[16] Kohs TCL, Liu P, Raghunathan V, et al. Severe thrombocytopenia in adults undergoing extracorporeal membrane oxygenation is predictive of thrombosis[J]. Platelets, 2022, 33(4):570-576. DOI:10.1080/09537104.2021.1961707.
[17] Six KR, Compernolle V, Feys HB. Platelet biochemistry and morphology after cryopreservation[J]. Int J Mol Sci, 2020, 21(3):935. DOI:10.3390/ijms21030935.
[18] 龚丽,米紫玥,孔玉洁,等. 保存期间血小板中外泌体浓度变化及其对凝血功能的影响[J]. 安徽医科大学学报,2022,57(8):1283-1288. DOI:10.19405/j.cnki.issn1000-1492.2022.08.020.
[19] 叶晓芳,吴会娥,陈玮媛,等. 红细胞和血小板临床输血疗效分析[J]. 国际医药卫生导报,2022,28(11):1543-1546. DOI:10.3760/cma.j.issn.1007-1245.2022.11.015.
[20] Shams Hakimi C, Fagerberg Blixter I, Hansson EC, et al. Effects of fibrinogen and platelet supplementation on clot formation and platelet aggregation in blood samples from cardiac surgery patients[J]. Thromb Res, 2014, 134(4):895-900. DOI:10.1016/j.thromres.2014.05.023.

单采血小板输注患者血小板聚集的风险因子探讨

Risk factors of platelet aggregation in patients undergoing apheresis platelet transfusion

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

[1]	蓝志科廖硕希胡运新孙永奇胡琼力. 双重抗血小板药物联合中药治疗进展性缺血性脑卒中的临床效果分析 [J]. 国际医药卫生导报, 2024, 30(24): 4079-4082.
[2]	李瑜萍黄育娜朱进华陈国兴林艳霞. 替格瑞洛与氯吡格雷在急性心肌梗死患者经皮冠状动脉介入中的效果 [J]. 国际医药卫生导报, 2024, 30(1): 109-111.